在没有心力衰竭的急性心肌梗塞后与SGLT2抑制剂使用相关的结果:一种倾向匹配的研究
Rochell Issa1,2, Tess Calcagno1, Tyler Canova3
1Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH, USA.
Angiology
|August 25, 2025
概括
在没有心力衰竭的急性心肌梗塞患者中,- 葡萄糖同载体-2 抑制剂 (SGLT2i) 降低了主要心血管不良事件和全因死亡率. 使用SGLT2i还降低了出血风险,这表明有心脏保护作用.
科学领域:
- 心脏病学
- 内分泌学
- 药理学
背景情况:
- - 葡萄糖共载体-2 抑制剂 (SGLT2i) 是已知的心力衰竭和糖尿病的治疗方法.
- 它们在没有心力衰竭的急性心肌梗塞 (AMI) 患者中的作用不太清楚.
研究的目的:
- 评估SGLT2i使用与AMI但没有心力衰竭史的患者心血管结局之间的关联.
主要方法:
- 使用 TriNetX 美国协作网络进行的回顾性倾向匹配队列研究.
- 分析了1440名匹配患者 (720名SGLT2i+ vs.
- 主要结局:在1年内发生重大心血管不良事件 (MACE).
主要成果:
- 使用SGLT2i与MACE显著降低 (17. 4%对22. 0%;OR 0. 746;P=. 028).
- 在SGLT2i使用者中,全因死亡率显著降低 (3. 1% 与 7. 6% 相比; OR 0. 389; P<. 001).
- 使用SGLT2i也与较低的严重出血风险有关.
结论:
- 在没有心力衰竭的患者中,SGLT2抑制剂可能提供心脏保护性益处,尽管残留混是可能的.
- 减少出血的新发现需要在前性研究中进一步调查.
相关概念视频
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Acute Coronary Syndrome I: Introduction
72
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
72


